American Heart Association

American Heart Association

December 01, 2015
2 min watch

VIDEO: Novel DAPT score calculator could help resolve uncertainties around therapy duration

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

ORLANDO — Laura Mauri, MD, MSc, of the Brigham and Women’s Hospital and Harvard Clinical Research Institute, Boston, discusses a novel score calculator that integrates patient characteristics influencing bleeding and ischemia to predict benefit with longer dual antiplatelet therapy.

“Clinicians have really been stuck with trying to decide how to treat their individual patients,” Mauri said.

She provides background for the “controversy and concern” surrounding therapy duration to treat patients with DAPT after acute coronary syndromes or PCI with stents, touching on lessons learned from the DAPT and PEGASUS trials and highlighting potential bleeding risks.

Mauri notes the limitations of subgroup analyses in clinical trials that “just tell us about one characteristic of a patient at a time” and described how “detecting discriminators” with the DAPT score stands to resolve that.

Mauri details data showing the calculator’s capability, including outcomes on rates of MI, stent thrombosis, mortality and bleeding in patients with varied DAPT scores.

“We think that this tool will be quite helpful to clinicians going forward in figuring out how to achieve benefit in those patients who can derive it.”